reports
AIM Delisting Reminder
AIM Delisting Reminder Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) AIM Delisting Reminder Oxford, UK, and Cambridge, MA, US, 11 February 2020 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, issues a reminder that, as previously announced and pursuant to AIM Rule 41, the Company’s ordinary shares of one penny nominal value (“Ordinary Shares”) will cease to be admitted to trading on AIM at 7.00 am on 24 February 2020. Accordingly, the final day of trading on AIM of the Company’s Ordinary Shares will be 21 February 2020. The Company’s ...
Director/PDMR Shareholding
Director/PDMR Shareholding Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) Notification of Transaction of Persons Discharging Managerial Responsibilities Oxford, UK, and Cambridge, MA, US, 10 February 2020 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces that it has received notification that on 7 February 2020, Dr Elaine Stracker, a Non-Executive Director of the Company, was assigned for no consideration warrants to acquire a total of 2,099,207 ordinary shares by Maky Zanganeh and Associates, Inc. (“MZA”). The Company has a con...
Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eur...
Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Receive $1.0 Million Milestone Payment from Eurofarma Milestone Based on Achievement of Patient Enrolment Target in Phase 3 Clinical Trials of Ridinilazole Oxford, UK, and Cambridge, MA, US, 6 February 2020 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announced that it achieved the first milestone under its license and collaboration agreement with Eurofarma Laboratórios SA (‘Eurofarma’). The $1.0 milli...
Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conferen...
Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conference Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Present at the 2020 BIO CEO & Investor Conference Oxford, UK, and Cambridge, MA, US, 4 February 2020 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that Mr Glyn Edwards, Chief Executive Officer, will present at the 2020 BIO CEO & Investor Conference on 10 February 2020 at 2:15pm EST in New York City. A live webcast of the presentation will be available in the Investors section of the Company's website, . A replay ...
Exercise of Restricted Stock Units
Exercise of Restricted Stock Units Summit Therapeutics plc (‘Summit’ or the ‘Company’) Exercise of Restricted Stock Units Oxford, UK, and Cambridge, MA, US, 27 January 2020 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announces that following the exercise of restricted stock units by former directors, the Company has issued 269,230 new ordinary shares of one penny each (the “New Ordinary Shares”). Application has been made for the admission to trading on AIM of the New Ordinary Shares, which will rank pari passu with the Company’s...
Summit Announces Management Update
Summit Announces Management Update Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces Management Update Oxford, UK, and Cambridge, MA, US, 24 January 2020 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announces that Dr David Roblin has resigned as Chief Operating Officer, Chief Medical Officer and President of R&D, effective 31 January 2020. “David has been instrumental in establishing our leadership position in new mechanism antibiotic development and launching our Phase 3 clinical trials of ridinilazole for the treatment of C. difficile infection,” said ...
Summit Announces BARDA Expands Ridinilazole Award by $8.8 Million to I...
Summit Announces BARDA Expands Ridinilazole Award by $8.8 Million to Include Additional NDA-Enabling Work Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces BARDA Expands Ridinilazole Award by $8.8 Million to Include Additional NDA-Enabling Work Total Committed BARDA Funding Increased to $62.4 MillionTotal Award Increased to up to $72.5 Million Oxford, UK, and Cambridge, MA, US, 23 January 2020 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, today announces that the Biomedical Advanced Research and ...
Holding(s) in Company
Holding(s) in Company TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:Summit Therapeutics PLCSedol BN40HZ01b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)Non-UK issuer 2. Reason for the notification (please mark the appropriate box or boxes with an “X”)An acquisition or disposal of voting rightsXAn acquisition or ...
Holding(s) in Company
Holding(s) in Company TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:Summit Therapeutics PLCSedol BN40HZ01b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)Non-UK issuer 2. Reason for the notification (please mark the appropriate box or boxes with an “X”)An acquisition or disposal of voting rightsXAn acquisition or ...
Summit Therapeutics: 1 director sold
A director at Summit Therapeutics sold 33,321,870 shares at 22p and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Notification of Transactions of Persons Discharging Managerial Respons...
Notification of Transactions of Persons Discharging Managerial Responsibilities Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) Notification of Transactions of Persons Discharging Managerial Responsibilities Oxford, UK, and Cambridge, MA, US, 15 January 2020 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces that it has received notification that on 14 January 2020, Mr Robert W. Duggan, a Non-Executive Director of the Company, sold a total of 33,321,870 ordinary shares and transferred a total of 4,998,279 warrants to various t...
Summit Therapeutics Launches Online Resource for Patients with C. diff...
Summit Therapeutics Launches Online Resource for Patients with C. difficile Infection Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics Launches Online Resource for Patients with C. difficile Infection Oxford, UK, and Cambridge, MA, US, 7 January 2020 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today launched , an online resource for patients with C. difficile infection (‘CDI’) and their caregivers. The site provides information about CDI, the role of the microbiome in CDI and Summit’s ongoing Phase 3 clinical trials of its investigational precision...
Holding(s) in Company
Holding(s) in Company TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:Summit Therapeutics PLCSedol BN40HZ01b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)Non-UK issuer 2. Reason for the notification (please mark the appropriate box or boxes with an “X”)An acquisition or disposal of voting rightsXAn acquisition or disposal of financial instruments An event changing the breakdown of voting rights Other...
Holding(s) in Company
Holding(s) in Company TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:Summit Therapeutics PLCSedol BN40HZ01b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)Non-UK issuer 2. Reason for the notification (please mark the appropriate box or boxes with an “X”)An acquisition or disposal of voting rights An acquisition or ...
Completion of $50 million Fundraising and Directorate Change
Completion of $50 million Fundraising and Directorate Change Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) Completion of $50 million Subscription and Placing and Directorate Changes Oxford, UK, and Cambridge, MA, US, 24 December 2019 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces that the subscription and placing of new ordinary shares and warrants (the “Fundraising”) to raise approximately $50 million, which was approved by shareholders at the Company’s general meeting held on 23 December 2019, has completed. The subscripti...
Award of Share Options
Award of Share Options Summit Therapeutics plc (‘Summit’ or the ‘Company’) Award of Share Options Oxford, UK, and Cambridge, MA, US, 24 December 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announces a grant of options over new ordinary shares of one penny nominal value (‘Ordinary Shares’) on 23 December 2019 to Mr Manmeet Soni, Dr Elaine Stracker and Dr Ventzislav Stefanov. The Company has also made a grant of share options to certain Company employees in line with the Company’s Long Term Incentive Plan. Share Option Award t...
Exercise of Restricted Stock Units
Exercise of Restricted Stock Units Summit Therapeutics plc (‘Summit’ or the ’Company’) Exercise of Restricted Stock Units Oxford, UK, and Cambridge, MA, US, 24 December 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces the exercise by Leopoldo Zambeletti, a Non-Executive Director of Summit, of restricted stock units (‘RSUs’) that entitled the holder to subscribe for an ordinary share of one penny nominal value at a subscription price of one penny per ordinary share. The RSUs were granted under the Company’s 2017 Remuneration Policy and were eligible for exercise for a ...
Result of General Meeting
Result of General Meeting Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) Result of General Meeting, Admission of Fundraising Shares and Directorate Changes Oxford, UK, and Cambridge, MA, US, 23 December 2019 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces that at a general meeting of the Company held today in London, in connection with the proposed subscription and placing of new ordinary shares to raise approximately $50 million announced by the Company on 6 December 2019 (the “Fundraising”), all of the resolutions were duly ...
Timetable Update
Timetable Update Summit Therapeutics plc(“Summit Therapeutics” or the “Company”) Timetable update for the proposed Subscription and Placing Oxford, UK, and Cambridge, MA, US, 19 December 2019 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces that, further to the announcement made on 6 December 2019 regarding a fundraising of approximately $50 million through a subscription and placing of new ordinary shares and warrants to existing investors, the expected date of Admission and commencement of dealings in the New Ordinary Shares on AIM ha...
Summit Therapeutics Reports Financial Results and Operational Progress...
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended 31 October 2019 Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended 31 October 2019 Oxford, UK, and Cambridge, MA, US, 17 December 2019 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today reports its financial results and provides an update on its operational progress for the third quarter and nine months ended 31 October 2019. ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.